ROQAFRoquefort Therapeutics plc

About Roquefort Therapeutics plc (ROQAF)

Roquefort Therapeutics plc (ROQAF) is a Biotechnology company headquartered in London, ENG, United Kingdom whose shares trade over-the-counter on the Pink tier.

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of: (1) Midkine antibodies with significant in vivo efficacy and toxicology studies; (2) Midkine RNA therapeutics with novel anti-cancer gene editing action; (3) Midkine mRNA therapeutics with novel anti-cancer approach; (4) STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and (5) MK cell therapy with direct and natural killer cell-mediated anti-cancer action.

Products and services

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of: (1) Midkine antibodies with significant in vivo efficacy and toxicology studies; (2) Midkine RNA therapeutics with novel anti-cancer gene editing action; (3) Midkine mRNA therapeutics with novel anti-cancer approach; (4) STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and (5) MK cell therapy with direct and natural killer cell-mediated anti-cancer action.

ROQAF key facts

Ticker symbol

ROQAF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

London, ENG, United Kingdom

Country of incorporation

GB

Year of incorporation

2020

Employees

5

Estimated market cap

$6.46M (as of May 13, 2025)

Shares outstanding

129,149,998

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2023)

Roquefort Therapeutics plc leadership

• Ajan Reginald — CEO
• Anthony Eastman — Corporate Secretary
• Martin Evans — Chief Scientific Officer

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with R